<br /> TheFly.com <br /> <br /> Portfolio Alerts <br /> Click the Portfolio Name or Symbol to see the research on thefly.com <br /> Main Portfolio matches: AUPH. <br /> <br /> TODAY, MAY 20, 2021 <br /> AUPH <br /> 16:08 <br /> Hot Stocks <br /> Aurinia to present 'supportive' AURORA 2 study interim analysis <br /> Aurinia Pharmaceuticals announced that a supportive interim analysis of its AURORA 2 continuation study will be presented at the upcoming European Alliance of Associations for Rheumatology 2021 Congress June 2-5, 2021. Subjects who completed one year of treatment in Aurinia's Phase 3 AURORA study were eligible to enroll in the two-year, blinded, controlled continuation study. The interim analysis to be presented at EULAR evaluated subjects with up to two years of total treatment: one year from AURORA 1 and up to one year in AURORA 2. Previously reported results from AURORA 1 and the Phase 2 AURA-LV study showed that compared with mycophenolate mofetil and low-dose steroids alone, the addition of voclosporin significantly increased the renal response rate and reduced proteinuria, as measured by urine protein creatinine ratio, in subjects with lupus nephritis at approximately one year of treatment. The interim analysis of AURORA 2 showed that subjects in the LUPKYNIS treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate at 104 weeks of treatment. "Following the enhanced renal response rates achieved in AURORA 1, these additional data show that LUPKYNIS also provides the ability to sustain positive outcomes over time," said Amit Saxena, M.D., Assistant Professor at the Department of Medicine at NYU Langone Medical Center. "The strong and growing pool of data available on LUPKYNIS clearly demonstrates the clinical value and safety of this therapy for a patient population that has historically been challenged with a lack of effective treatment options."